Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
Annals of Oncology2014Vol. 25(12), pp. 2378–2385
Citations Over TimeTop 10% of 2014 papers
Hélène Blons, Jean‐François Emile, Karine Le Malicot, C. Julié, Aziz Zaanan, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean‐Luc Van Laethem, J. Thaler, John Bridgewater, L. Nørgård-Petersen, Eric Van Cutsem, Côme Lepage, Mohamed-Ayman Zawadi, Ramón Salazar, Pierre Laurent‐Puig, Julien Taı̈eb
Related Papers
- → Interstitial Lung Disease Associated with Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin(2010)4 cited
- The Efficacy and Toxicity of FOLFOX Regimen（A Combination of Leucovorin and Fluorouracil with Oxaliplatin）as First-Line Treatment of Metastatic Colorectal Cancer(2009)
- → Adjuvant FOLFOX Treatment for Stage III Colorectal Cancer: Why Patients Quit FOLFOX?(2017)
- Oxaliplatin, 5-Fluorouracil, Leucovorin 복합항암화학요법 중에 발생한 간질성 폐질환 1예(2010)
- → Two Cases of Unresectable Advanced Gastric Cancer who could Resume Oral Intake following Tumor Response to Fluorouracil + folinate + oxaliplatin Therapy(2022)